Tate Michael Truett

CFO Tate Truett sold 12,001 shares at blended avg $123.81 on 2026-02-17, reducing stake 5.9%; stock now -27.8% in 30 days

Tate Michael Truett (CFO) executed 5 separate sales totaling 12,001 shares for $1,485,784.44 on 2026-02-17 at prices ranging from $122.16 to $126.34, reducing his holdings from 204,084 shares to 192,083 shares. His cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 45.00%, but his same-ticker history at ALAB is notably stronger: all 5 prior sales at this ticker exhibited negative 90-day returns, meaning 100% were well-timed (stock declined after each sale). The current environment presents a sharp reversal: ALAB stock has fallen 27.8% in the 30 days since this transaction and 47.4% from its 52-week high, while the company reported FY net income as negative despite showing +242.2% annual revenue growth. The CFO's historical skill at exiting before declines at this ticker, combined with the stock's subsequent severe drawdown and the company's negative full-year profitability, suggests his timing aligned with deteriorating fundamentals.

CFO Tate Michael Truett sold 11,430 shares in 4 separate transactions for $1,653,859.17 on 2025-11-17; stock now trading 43.6% below 52-week high.

Tate Michael Truett, CFO of Astera Labs, executed 4 separate sales totaling 11,430 shares for $1,653,859.17 at blended average price $144.69, occurring on a day when the stock has declined 43.6% from its 52-week high and is down 9.2% over the past 30 days. His prior 5 trades at ALAB (all sells executed in August 2025) showed a 100% rate of well-timed exits at the 90-day mark, with all producing negative 90-day returns ranging from -21.5% to -9.0%. The company's fundamentals remain strong with $230.6M quarterly revenue and $91.1M net income, though on a P/E of 120.35 and 52-week price weakness, his latest sale pattern parallels his earlier August exits that preceded stock declines. This represents a 5.6% reduction in his 192.3K share post-transaction holdings.

CFO Tate Michael Truett sold 18,861 shares at blended average price $183.51 for $3,461,184.47 on 2025-08-18

Tate Michael Truett (CFO) executed two separate sales totaling 18,861 shares for $3,461,184.47, reducing his position from 476,142 to 457,281 shares (a -4.0% reduction). The sales occurred at $183.83 and $183.17 per share, well above the current market price of $172.45 and near the 52-week high of $193.64, suggesting favorable execution timing. Astera Labs exhibits high-growth fundamentals (annual revenue growth of +242.2% and net income of $51,219,000 in the latest quarter) despite a historically unprofitable full fiscal year, alongside a stretched valuation (P/E of 287.42 and recent 90-day appreciation of +82.9%). Notably, the CFO executed five sales at ALAB in the prior week (2025-08-07 and 2025-08-12), indicating an ongoing pattern of liquidity events by this insider.

CFO Tate Michael Truett sells 100,000 ALAB shares (19.9% of holdings) for $19.1M on 2025-08-12

Tate Michael Truett, Chief Financial Officer of Astera Labs, executed 3 separate sales totaling 100,000 shares for $19,118,988.01 on 2025-08-12, reducing his holdings from 501,496 shares to 401,496 shares. The sales occurred at prices ranging from $190.82 to $192.52 (blended average $191.19), near the stock's 52-week high of $193.64. This represents a substantial 19.9% reduction in his position. The timing is notable given the stock's recent momentum: the company has seen a 30-day return of +106.5% and 90-day return of +110.6%, though the company's fundamentals remain mixed with a P/E of 317.82 and unprofitable full-year results despite recent quarterly profitability of $51,219,000.00. Across the insider's cross-ticker history, his 20 prior sells showed an average 90-day return of +20.1% with a well-timed rate of 55.56%, though at ALAB specifically, his prior 4 recent sales on 2025-08-07 lack measurable outcomes and his May 2025 sale showed a +3.3% 30-day return.

CFO Tate Michael Truett sold 100,000 shares (16.6% of holdings) for $17.1M at blended average of $171.38 on 2025-08-07.

Tate Michael Truett, CFO of Astera Labs, executed 4 separate sales totaling 100,000 shares for $17,138,484.75 on 2025-08-07, reducing his holdings from 601.5K to 501.5K shares. The sale occurred when the stock was trading near its 52-week high of $179.43, with the company showing strong recent momentum: 30-day +87.1% and 90-day +104.5% gains. However, the fundamental backdrop is mixed—while the latest quarter showed revenue of $191.9M and net income of $51.2M with annual growth of +242.2%, the company was unprofitable over its most recent full fiscal year, and carries an elevated P/E of 299.05. The CFO's prior sales at ALAB (5 trades on 2025-05-30) showed mixed near-term outcomes with 30-day returns ranging from -2.1% to +3.3%, offering limited predictive insight into this sale's timing quality.

CFO Tate Michael Truett sold 500,000 shares ($45.1M) across 7 transactions on 2025-05-30; post-sale holdings of 619.0K shares represent -44.7% reduction.

Tate Michael Truett, CFO of Astera Labs, executed 7 separate sales totaling 500,000 shares for $45,113,207.95 on 2025-05-30, representing a -44.7% reduction in his pre-transaction holdings from 1.12M to 619.0K shares. The blended average sale price of $90.23 contrasts with the current price of $95.09, meaning the sales occurred below current market levels. In Truett's cross-ticker track record, his prior sells showed a 90-day well-timed rate of 94.12%, but at ALAB specifically, his 2 most recent measurable sales (2025-02-26 and 2025-02-18) posted 90-day outcomes of +18.2% and -1.9%, with only 1 of 2 qualifying as well-timed by the 90-day metric. The company's fundamentals show extreme valuations (P/E of 380.36) despite trailing annual net losses, alongside exceptional revenue growth of +242.2% year-over-year, creating a volatile backdrop for a large proportional reduction in executive holdings.

CFO Tate Michael Truett sold 9,107 shares of ALAB for $825,715.27 at blended $90.67; holds 235.1K shares post-sale.

Tate Michael Truett executed three separate sales totaling 9,107 shares for $825,715.27 on 2025-05-16, reducing his holdings by 3.7%. The blended sale price of $90.67 sits below the current price of $94.46, meaning the stock has appreciated since the transaction—similar to his most recent ALAB sale on 2025-02-26, which saw a 30-day decline of -26.4%. Notably, across his five prior trades at ALAB, all four measurable 90-day outcomes showed declines (-1.9%, -41.8%, -41.2%, -40.8%), establishing a 100% pattern of well-timed sales at this specific ticker. The company carries an extreme P/E of 377.84 with annual revenue growth of +242.2%, though full-year net income was negative—characteristics often associated with high-valuation risk. This sale merits observation given the insider's demonstrated timing accuracy at ALAB and the company's valuation profile.

Astera Labs CFO Tate Michael Truett sold 125,800 shares at $82.53 for $10.4M; stock now down 49.0% from 52-week high.

Tate Michael Truett, Chief Financial Officer of Astera Labs, sold 125,800 shares (125.8K shares) at $82.53 on 2025-02-26, reducing his holdings by 10.1% to 1,118,996 shares. The sale occurred at a price $8.18 above the current market price of $74.35, and the stock has declined 49.0% from its 52-week high of $145.81. Astera Labs is an unprofitable company with net income of $-7,593,000.00 (latest quarter), despite strong revenue growth of +242.2% year-over-year. His prior trades at Astera Labs show mixed 30-day outcomes (ranging from +16.9% to +22.1% on prior December and February sales), though none are yet measurable at the 90-day mark. The sale occurs in the context of significant recent stock weakness (−17.8% over 30 days, −28.0% over 90 days), which post-dates the transaction and therefore does not characterize the timing decision itself. This is a material reduction by a financial officer of a high-growth but currently unprofitable business.

CFO Tate Michael Truett sells 34,474 shares of ALAB at $92.07 for $3.2M; stock down 39.4% from 52-week high, 28.9% in 30 days

Tate Michael Truett, Chief Financial Officer of Astera Labs, sold 34,474 shares at $92.07 on 2025-02-18, reducing his holdings by 12.4%, a discretionary open-market transaction totaling $3,174,028.07. The stock has declined sharply: -28.9% over 30 days and -39.4% from its 52-week high of $145.81, while the company operates unprofitably (net income of -$7,593,000 in the latest quarter) despite strong revenue growth of 242.2%. Across his open-market transaction history at other tickers, this insider's 20 prior sells averaged +20.8% 30-day returns post-sale, but his five prior ALAB-specific sales (all in December 2024) have not yet accumulated 90-day outcome data. The timing context shows stress in the equity: persistent weakness (current price $88.43 vs transaction price $92.07) and the CFO reducing a material stake during a period of significant downward momentum and unprofitability, though no scheduled plan or disclosed rationale is indicated by available facts.

CFO Tate Truett sold 16,000 shares (6 transactions) for $1.9M at $117.84 avg, holding 1.41M shares post-sale

Tate Truett, CFO of Astera Labs, executed 6 separate sales on 2024-12-04 totaling 16,000 shares for $1,885,472.22, representing a 1.1% reduction in his 1.43M-share position. The stock is currently at $120.40, near its 52-week high of $120.40, and has surged +22.6% over 30 days and +201.0% over 90 days. Notably, Truett executed similar sales on 2024-12-03 (5 prior trades at ALAB), suggesting a deliberate reduction pattern during a period of significant stock appreciation. His cross-ticker trading history shows 20 prior sells with a 0.00% well-timed rate at the 90-day mark, indicating his past sales have not preceded stock declines; however, the recent 90-day surge (+201.0%) and proximity to the 52-week high suggest he is selling into strength rather than at depressed levels.